• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Twelve Month Donor Deferral for MSM May Not Increase Risk of Transfusion-Transmitted HIV

March 22, 2013

A study published in the journal Vox Sanguinis suggests that a policy of 12-month donor deferral for men who have sex with men (MSM) would not result in a significantly greater risk of transfusion-transmitted HIV infection than a policy of lifetime deferral. Using donation and infection surveillance data from England and Wales between 2005 and 2007, researchers estimated that 12-month deferral would result in a 0.5% greater risk than lifetime deferral, reflecting one additional HIV-infected donation every 455 years. The authors also suggest that expected rates of transfusion-transmitted HIV would vary substantially depending on compliance with a deferral policy. In November 2011, following recommendations from the UK Department of Health, 12-month deferral for MSM was implemented in England, Wales, and Scotland. Although the policy was recently reexamined, MSM are currently excluded from donating blood in the United States.

References

1.    Davison KL, Conti S, Brailsford SR. The risk of transfusion-transmitted HIV from blood donations of men who have sex with men, 12 months after last sex with a man: 2005-2007 estimates from England and Wales. Vox Sang 2013

2.    U.S. Food and Drug Administration.  Blood Donations from Men Who Have Sex with Other Men Questions and Answers.  Accessed March 18, 2013.  http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/QuestionsaboutBlood/ucm108186.htm

Filed Under

  • Blood Donation
  • News

Recommended

  • KEL-Antigen Modulation is Important for Anti-KEL Immunoprophylaxis

  • Blood Cell Salvage Decreases Transfusions After Decannulation from Extracorporeal Membrane Oxygenation (ECMO)

  • RBC Transfusions and Alloimmunization in Patients Taking Daratumumab

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley